NAD+ (500 mg Vial) Dosage Protocol

Supplies Needed

Supply estimates follow the calculation schedule above and assume one new syringe plus two alcohol swabs per day.

• Peptide Vials (NAD+, 500 mg each):
  • 8 weeks: 11 vials (approximately 5,075 mg calculated)
  • 12 weeks: 16 vials (approximately 7,875 mg calculated)
  • 16 weeks: 22 vials (approximately 10,675 mg calculated)
• Insulin Syringes (U-100, 1 mL):
  • 8 weeks: 56 syringes
  • 12 weeks: 84 syringes
  • 16 weeks: 112 syringes
• Bacteriostatic Water (10 mL bottles):
  • 8 weeks: 33 mL → 4 bottles
  • 12 weeks: 48 mL → 5 bottles
  • 16 weeks: 66 mL → 7 bottles
• Alcohol Swabs:
  • 8 weeks: 112 swabs — 2 boxes required (100 swabs each)
  • 12 weeks: 168 swabs — 2 boxes required (100 swabs each)
  • 16 weeks: 224 swabs — 3 boxes required (100 swabs each)

Sharps safety: Place used needles and syringes in an FDA-cleared sharps container immediately after use; never reuse them.

View Supplier

View Supplier

View Supplier

View Supplier

NAD+ 500 mg Protocol Overview

The 500 mg format makes concentration and vial yield the central questions. With a 3.0 mL final volume, each milliliter contains 166.67 mg and each U-100 unit contains about 1.67 mg. The chart applies the same calculation to every row: milligrams divided by 166.67 mg/mL gives the liquid volume, and milliliters multiplied by 100 gives the U-100 syringe marking.

50 mg per administration: 50 ÷ 166.67 = 0.30 mL = 30 units.
75 mg per administration: 75 ÷ 166.67 = 0.45 mL = 45 units.
100 mg per administration: 100 ÷ 166.67 = 0.60 mL = 60 units.

Container strength does not establish a dose. A 500 mg vial changes the concentration, the volume per injection, and the number of vials needed for a selected calculation period. It does not prove that a starting dose, maintenance dose, daily dose, or number of times per week is medically appropriate. That distinction keeps the arithmetic useful without turning a convenience calculation into clinical guidance.

NAD+ 500 mg Reconstitution Math

• Three equations control the NAD+ dosage chart:
• 1. Concentration: 500 mg ÷ 3.0 mL = 166.67 mg/mL.
• 2. Injection volume: selected mass ÷ 166.67 mg/mL = mL.
• 3. U-100 syringe marking: mL × 100 = units.

For example, a 25 mg arithmetic example equals 0.15 mL, or 15 U-100 units. A 125 mg example equals 0.75 mL, or 75 units. These values demonstrate the conversion formula only; they are not additions to the schedule. Calculate with the full concentration first and round the final unit result last so early rounding does not distort the volume.

A U-100 marking describes liquid volume. It does not describe the biological activity of NAD+, and it is not the same as an international unit. Confirm both the syringe scale and the prepared concentration before interpreting any row.

Vial Yield and Supply Planning

At 166.67 mg/mL, the 3.0 mL container holds 500 mg in total. Dividing that total by a selected amount estimates the theoretical yield before accounting for residual liquid in the vial or syringe.

50 mg calculation: 10 complete administrations per vial.
75 mg calculation: 6 complete administrations, with about 50 mg remaining.
100 mg calculation: 5 complete administrations per vial.

The supply totals round vial counts upward so the modeled period contains enough total mass. They should not be used to extend a product beyond its verified storage or discard instructions. They also do not compensate for dead space, transfer loss, or an incomplete withdrawal.

Readers comparing this page with the NAD+ 1000 mg protocol should expect different U-100 markings and vial counts even when the selected milligram amount is the same. The 1000 mg page uses twice the concentration at the same 3.0 mL final volume, so its calculated liquid volume is half as large.

What Human NAD+ Studies Actually Used

Direct human research on administered NAD+ is limited. A pharmacokinetic pilot study gave 750 mg by intravenous infusion over six hours and measured plasma and urinary metabolites. It described disposition during supervised IV administration, but it did not evaluate a subcutaneous injection protocol, a daily maintenance schedule, or the 50–100 mg chart on this page.

An observational report combined NAD+ with enkephalinase-inhibiting therapy in a substance-use-disorder setting. Because the intervention was combined and the design was not controlled, it cannot isolate the effect of NAD+ or establish a general injection protocol.^[2]

A 2026 retrospective tolerability pilot is especially relevant to the 500 mg search because participants received 500 mg intravenous NAD+ on four consecutive days. Gastrointestinal symptoms, increased heart rate, and chest pressure were reported during infusions, and the authors characterized the findings as exploratory. The study does not establish that 500 mg per session is an optimal dosage, nor can its supervised IV regimen be converted into a SubQ dose or an injection dosage per day.

A systematic review of NAD+ and NADH studies found varied formulations, routes, populations, and outcomes. A newer review reported no eligible outcomes trials of IV or intramuscular NAD+ itself for anti-aging or wellness indications. Many human studies instead evaluate oral precursors such as nicotinamide riboside or nicotinamide mononucleotide. Those compounds may raise NAD-related metabolites, but their milligram amounts cannot be translated directly into a dose of injected NAD+.^[6]

500 mg IV Research Is Not a Subcutaneous Schedule

Route is part of the protocol, not a detail that can be ignored. IV therapy places a solution directly into the bloodstream under medical supervision. A subcutaneous injection places a smaller volume beneath the skin and follows a different absorption path. Intramuscular administration is different again. Evidence from one route does not establish dosage and frequency for another.

That matters when interpreting searches such as NAD+ 500 mg injection dosage per week, mg per injection, 2-3 times per week, or dosage per day. Published 500 mg and 750 mg studies used IV settings. They do not validate daily SubQ injections, three times per week, a lower dose used more often, or a higher dose used less often.

The primary chart therefore answers a narrower question: if a 500 mg vial is prepared to 3.0 mL, what volume corresponds to the displayed mass? It does not select the right dose, decide the number of sessions, or claim that the community-reported pattern has demonstrated clinical benefits.

NAD+ Injection Safety and Product Quality

Sterility and ingredient quality are separate from dosage math. The FDA has reported adverse events after injectable compounded products used food-grade NAD+ that was not suitable for sterile compounding, including chills, shaking, vomiting, and fatigue.^[9] An FDA warning letter also described a compounded NAD+ lot associated with hypotension, uncontrollable shaking, shivering, and body aches; testing found excessive endotoxin.^[10] These reports do not evaluate this supplier or this chart, but they show why concentration alone cannot establish product quality or safety.

General injection guidance supports using a new sterile needle and syringe, preparing a clean work area, rotating injection sites, and placing used sharps in an appropriate container immediately after use.^[11][12] General technique resources do not endorse NAD+ injections or the community schedule shown here.

Confirm the syringe is U-100 before using the unit conversions. Keep mass and volume separate: 100 mg is compound mass, while 0.60 mL is its calculated volume at 166.67 mg/mL. Do not use a solution that is cloudy, discolored, contains visible particles, or was stored outside verified conditions. Do not transfer IV research amounts to subcutaneous or intramuscular use.

NAD+ Storage and Handling

Use the exact product label, lot documentation, and validated stability instructions as the controlling source. The supplier page documents the identity and availability of the 500 mg product; it is not evidence for a clinical dose or a universal use-by period.^[13]

• Before preparation: keep the sealed product dry, protected from light, and within the manufacturer’s labeled temperature range.
• After preparation: label the vial with the compound, 166.67 mg/mL concentration, and preparation date; refrigerate at 2–8°C (36–46°F) and protect from light.
• Inspection: do not use a solution that is cloudy, discolored, contains visible particles, or has been stored outside verified conditions.
• Discard timing: do not infer a universal period from the 500 mg strength alone. Follow product- and preparation-specific stability information.

NAD+ 500 mg Frequently Asked Questions

How much bacteriostatic water does this NAD+ 500 mg chart use?
The page uses a 3.0 mL final volume. Dividing 500 mg by 3.0 mL produces 166.67 mg/mL. A different final volume requires every milliliter and U-100 conversion to be recalculated.

How many U-100 units equal 50 mg?
At 166.67 mg/mL, 50 mg equals 0.30 mL, or 30 units on a U-100 syringe.

How many units equal 100 mg per injection?
At the concentration used here, 100 mg equals 0.60 mL, or 60 U-100 units.

How many doses are in a 500 mg vial?
Theoretical yield depends on the selected mass: ten 50 mg calculations, six complete 75 mg calculations with about 50 mg remaining, or five 100 mg calculations. Real-world withdrawal loss may reduce recoverable volume.

Is there a clinically established NAD+ injection dosage per day?
No general daily injection dosage has been established by controlled human trials. Published parenteral evidence is limited and concerns supervised IV use, so this chart is community-reported calculation context rather than a clinical recommendation.

Does a 500 mg vial require a lower dose than a 1000 mg vial?
No. Vial strength determines total available mass and, with the final volume, concentration. It does not independently determine a starting dose, maintenance dose, or injection frequency.

Can IV NAD+ research be used to set a SubQ protocol?
No. The route, infusion duration, monitoring, and exposure conditions differ. Existing 500 mg and 750 mg IV studies do not validate a subcutaneous schedule.